GeoVax Labs, Inc., a clinical-stage biotechnology company, has announced completion of required release testing for GEO-MVA clinical supplies, with final product release scheduled for early April. This development represents a significant step toward initiating the company's planned pivotal Phase 3 clinical study for its vaccine targeting protection against mpox and smallpox.
The availability of GEO-MVA clinical material advances the program toward an immune bridging study designed in accordance with guidance from the European Medicines Agency. This study, scheduled to initiate in the second half of this year, is a critical component of the EMA's expedited development pathway, which could lead to regulatory Marketing Authorization. The study aims to demonstrate comparability to an approved MVA vaccine using immunological endpoints.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that the availability of cGMP clinical material marks a significant advancement for the GEO-MVA program. With final product release expected shortly, the company is entering the final preparatory phase ahead of initiating the immune bridging study, positioning GeoVax at what Dodd described as "a pivotal inflection point, moving toward potential regulatory approval and subsequent commercialization."
Parallel to clinical progress, GeoVax has initiated outreach discussions supporting potential procurement and preparedness contracting. These discussions include organizations that influence or directly procure vaccines for national stockpiles, military preparedness programs, and international outbreak response initiatives. According to Dodd, these engagements underscore "the increasing recognition of the critical need to expand global supply of MVA-based vaccines."
The GEO-MVA program addresses what the company describes as a significant and well-recognized gap in global vaccine preparedness. Recent mpox outbreaks and evolving epidemiological patterns have reinforced the need for sustained preparedness, including expanded manufacturing capacity and diversified supply sources. The current supply of MVA vaccine is concentrated with a single commercial manufacturer, limiting redundancy in a platform considered essential for protection against both mpox and smallpox.
GeoVax believes GEO-MVA has the potential to serve as an important additional source of MVA vaccine supply supporting national stockpile programs, global outbreak response efforts, and military and biodefense preparedness initiatives. Following successful completion of the planned study, GEO-MVA is expected to advance toward regulatory submission and potential commercialization as an additional source of MVA vaccine supply for global preparedness and biodefense programs.
For more information about GeoVax and its programs, visit https://www.geovax.com.
